Technique is important
Editor-As a retired front-row forward of over 30 years' playing experience in Wales and England I never experienced, or witnessed, any type of injury as described in Bourke's article. 1 From an early age I was taught the correct positioning of my feet, legs, neck, and back. Throughout my amateur career I kept comparatively fit and as a nurse never experienced any back problems, even before the current "no lifting" environment. I firmly believe that my sport allowed me to lift correctly, without putting any undue strain on my back.
The scrum in rugby union allows players of different shapes (tall and thin, fat and short) to participate in the game and to remove its competitive edge would turn the game into one that would severely restrict the attraction to many young people. Scrummaging was what I did well (I was very, very good at it) and what got me into many teams that normally wouldn't have touched me as I wasn't a speed merchant or particularly good in open play. I hated uncontested scrums, and I am sure that if you polled front-row forwards they would say exactly the same. We know the risks and are mindful of these when competing.
Reality check is needed
Editor-I write with reference to Bourke's personal view.
1 There is no doubt that paraplegia is absolutely devastating. However, let's get things in proportion-based on Bourke's numbers, the risk of contracting a spinal injury is tiny. Bourke states he attends 25 home matches per season and has done so for 30 years; that makes 750 matches. I assume there are roughly the same number of away matches, making 1500 games in 30 years. A typical game may expect a scrummage every five minutes or so, say eight per half or 16 per match. That's 24 000. And in those, two consenting adults-fully aware of the risk-have suffered lifelong injury: a rate of 0.000083 for Nottingham Rugby Football Club. Still devastating, I agree.
But on the basis of this, is Bourke really suggesting we should stop a fantastic sport enjoyed by so many? If that's the case, horse riding needs to be banned completely immediately, and cycling should only occur on designated, off-road facilities when wearing Kevlar coveralls. If we really want to do something helpful let's look carefully at the road; there are more unnecessary deaths and severe injuries here in the United Kingdom than anywhere else.
I'm not saying we can ignore rugby injuries; the English Rugby Football Union has been mindful of these risks for a long time and the International Rugby Board referees' manual has clear guidance on minimising injury. We need to keep the balance of risks and benefits in proportion; scrummaging is an integral part of the union game and should not be lost as technical ability here may be one of the sporting skills that decides between great teams. Also, players have a choice, if they don't want to scrummage then they can play rugby league, where skills are just as important but strong in different aspects of the game. 
Malcolm Cameron consultant surgeon

Engage, don't ban
Editor-With reference to Bourke's personal view, 1 I caution relying on personal experience rather than systematic study of the risk from contested scrums in rugby. In my six years in rehabilitation medicine, I have encountered six people with spinal cord injuries from playing rugby, one of whom was rugby league, and only one was injured in a scrum. At various times since their injury, not one regretted having played rugby and just felt they were the "unlucky" ones.
During my comparatively short career I have encountered hundreds of people with DPP/REX Letters spinal injuries from road traffic crashes, many who regret the risks they took at the time. Although it is difficult to draw direct risk comparisons between the two, I will be much more concerned when my children want to start driving than when they want to play rugby, even in a scrum. If there is a risk with the scrum, it does seem to be with the engagement and perhaps reviewing this aspect, yet still allowing the scrum to be contested, might lower the risk without loss of "the essence" of the sport?
However, ongoing study of the risks of spinal cord and other injuries from various activities needs to be routine, not just restricted to high level participants, as is the current practice of the Rugby Football Union. Only with accurate data can we inform those involved of the risks and how they might be minimised without losing the benefits and attractions of such activities. The call for a ban on contested scrums by Bourke also raises the issue of the role of the medical profession in the regulation of sports, which remains controversial even in combative sports such as boxing. 
Protecting the heart may not protect the public health
Editor-Britton raises the profile of what will continue to be an informed debate over the role of alcohol in protecting the heart from vascular disease. 1 However, the picture is not complete and, as she points out, the media could take a rather skewed view of the benefits of drinking.
In older people the harmful effects of alcohol may manifest themselves in ways other than cardiac events. For example, 50% of older people with alcohol misuse present to secondary care services with falls.
2 The cardioprotective message is also clouded by the lack of any clear evidence that alcohol is beneficial to older people's health in general.
The prevalence of alcohol misuse in older people has risen steeply in the UK over the past 20 years, by 50% in men and by 100% in women. Coupled with a projected rise in over 65s of 50% between 2001 and 2031, there is a risk of a greater public health burden in years to come.
There may be alternatives to reducing cardiovascular risk other than the use of a psychoactive drug with the potential for adverse non-cardiac effects. Furthermore, for the public health, the "prevention paradox" suggests that older people drinking at moderate levels may pose the greatest public health burden. 3 The media, government, and drinks industry would do well to consider the bigger picture of alcohol related burden in people approaching their 60s before potentially misinforming the public of the benefits of alcohol. 
Pulmonary tuberculosis
Chest radiograph can appear normal in immunocompromised patients
Editor-Campbell and Bah-Sow describe the varied patterns of abnormality in chest radiographs in patients with pulmonary tuberculosis, appearances often being less specific in immunocompromised patients.
1
We agree that a high index of suspicion is necessary in such patients and highlight the inadequacy of a chest radiograph in excluding pulmonary tuberculosis.
Our hospital is in a major suburban town in Greater London and has an ethnically diverse and unusually mobile population. In the past 12 months, 16% of cases of pulmonary tuberculosis (excluding mediastinal lymphadenitis and pleural disease) had co-infection with HIV. In one such case the chest radiograph was completely normal while sputum was smear positive.
This occurs more often than we expected: in 2004 a paper from Addis Ababa showed that 9.2% of patients with HIV and culture proved pulmonary tuberculosis had a normal chest radiograph.
2 An earlier paper from Rome showed that 9% of patients who were HIV positive and sputum culture positive had a normal chest radiograph and were sputum smear negative. Although these patients were no different in demographic characteristics, degree of immunosuppression, or Mycobacterium tuberculosis drug susceptibility pattern, they had an increased risk of death and shorter median survival.
3 In a series from New York, 14% of patients with coinfection (HIV or culture positive for tuberculosis) had a normal chest radiograph, and this rose to 21% when patients with low CD4 counts were considered ( < 200). Most paediatric tuberculosis in developed countries is in children born overseas. The diagnosis and prompt treatment of latent infection, particularly in immigrant and refugee children, is therefore of considerable importance. Admittedly, the diagnosis of tuberculosis disease in children is difficult, with at least half of children with the disease being asymptomatic at presentation. 5 Immunological investigations (Mantoux testing and blood based assays) may be comparatively insensitive, especially in younger children, and are currently unavailable in many endemic regions. Early morning gastric washings (to isolate mycobacteria from sputum swallowed overnight) is a key diagnostic investigation in younger children in high incidence areas, with a culture yield of more than 50%. 4 Similarly, induced sputum samples have a higher yield (80%) in older children. Laryngeal swabs are, however, poorly tolerated, less well studied, and rarely helpful. 
Ethnic differences in risks of adverse reactions
Is personalised drug treatment better with pharmacokinetic modelling?
Editor-McDowell et al conclude that patients from different ethnic groups have different risks for important adverse drug reactions on the basis of a meta-analysis of adverse reactions due to drugs used in cardiovascular medicine. 1 Data are sparse, and regulators should ask for better data before licensing.
The use of pharmacokinetic and pharmacodynamic modelling would greatly facilitate this process. The European Commission sponsored a workshop to facilitate the incorporation of such modelling studies into drug development. Data from 1997 on naratriptan, a serotonin agonist treatment for acute migraine, used a population approach and Bayesian predictions to examine the pharmacokinetic and pharmacodynamic relations for oral naratriptan during phase II clinical trials. Hepatic clearance of naratriptan declined with age and use of hormone contraception, potentially increasing the likelihood of adverse events leading to product labelling restrictions for elderly patients and leading to higher efficacy in women.
3
In tobacco smokers and black patients the hepatic clearance was increased, leading to lower exposure to naratriptan.
A population based, pharmacokinetic and pharmacodynamic approach as exemplified by naratriptan should be encouraged as a routine component of early human drug development, which could predict the need for special precautions and potential adverse events arising from differing circulating drug concentrations arising from environmental factors (such as smoking), ageing, and ethnicity. 
NICE work
Nice try
Editor-The reviews of NICE's (the National Institute for Health and Clinical Excellence) work 1 and its frustrations 2 miss the point: NICE has failed the objective of having "a leading role in healthcare priorities" because it cannot do otherwise.
The evidence of failure is bioeconomic: because new drugs risk physical and financial harm, recently shown dramatically with an immune stimulant, the pharmaceutical industry now mostly produces timid variants of existing drugs. Even when novelty is sought but fails, the high cost of production ensures that a poor drug is taken to market instead of being scrapped. Since most new drugs therefore have little or no advantage over those already available, NICE's acceptance of 80% 1 is clear evidence of failure; success would be rejection.
The reason NICE cannot but fail is biosocial-societies won't allow definition of a worthwhile level of benefit, let alone cost benefit: to the sick patient, one chance in a million, one extra life saved, even one extra day's health, are all equally desirable-try anything, regardless of its worth or cost, for the dubious reason that "worth" can only be personal and "anything is better than nothing." From these absurdities, it follows that anything becomes desirable, regardless of cost and quality.
If the government's objective had been therapeutic quality, NICE might have helped educate society about the infinite uselessness of the infinite statistic, although the great effort needed by the antismoking lobby with its very finite statistic, shows it wouldn't have been easy. Now, apart from the small cost savings of bureaucratic delay, NICE even fails in its original political purpose as a cost-cutting exercise; it's not a nice try.
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